Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Neurobiology of Disease

• Publication date

  2014-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.nbd.2014.04.018PMID 24807206
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential effects of angiotensin II receptor blockers on Aβ generation.

  2014cited by this paper
• Brain amyloid-β oligomers in ageing and Alzheimer's disease.

  2013cited by this paper
• A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists

  2013cited by this paper
• Endothelial TRPV4 channels mediate dilation of cerebral arteries: impairment and recovery in cerebrovascular pathologies related to Alzheimer's disease

  2013cited by this paper
• Effect of angiotensin II on spatial memory, cerebral blood flow, cholinergic neurotransmission, and brain derived neurotrophic factor in rats

  2012influential reference
• Angiotensin II-inhibition: effect on Alzheimer's pathology in the aged triple transgenic mouse.

  2012cited by this paper
• Age-Dependent Rescue by Simvastatin of Alzheimer's Disease Cerebrovascular and Memory Deficits

  2012cited by this paper
• Immunotherapy for Alzheimer disease—the challenge of adverse effects

  2012cited by this paper
• Associations of Anti-Hypertensive Treatments with Alzheimer's Disease, Vascular Dementia, and Other Dementias

  2011cited by this paper
• Angiotensin II-inhibiting drugs have no effect on intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of Alzheimer's disease.

  2011cited by this paper
• Amyloid β-Induced Impairments in Hippocampal Synaptic Plasticity Are Rescued by Decreasing Mitochondrial Superoxide

  2011cited by this paper
• Central Angiotensin II Stimulation Promotes β Amyloid Production in Sprague Dawley Rats

  2011cited by this paper
• Facilitation of Hippocampal Synaptogenesis and Spatial Memory by C-Terminal Truncated Nle1-Angiotensin IV Analogs

  2011cited by this paper
• Neurovascular function in Alzheimer's disease patients and experimental models

  2011cited by this paper
• The brain RAS and Alzheimer's disease.

  2010cited by this paper
• Selective in vivo antagonism of endothelin receptors in transforming growth factor-beta1 transgenic mice that mimic the vascular pathology of Alzheimer's disease.

  2010cited by this paper
• Protective Effects of Intranasal Losartan in the APP/PS1 Transgenic Mouse Model of Alzheimer Disease

  2010cited by this paper
• High‐molecular‐weight β‐amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients

  2010cited by this paper
• Transgenic mice overexpressing APP and transforming growth factor-beta1 feature cognitive and vascular hallmarks of Alzheimer's disease.

  2010cited by this paper
• Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis

  2010cited by this paper
• Antihypertensive agents and prevention of dementia

  2010cited by this paper
• Nonhypotensive Dose of Telmisartan Attenuates Cognitive Impairment Partially Due to Peroxisome Proliferator-Activated Receptor-&ggr; Activation in Mice With Chronic Cerebral Hypoperfusion

  2010cited by this paper
• Gene knockout of insulin-regulated aminopeptidase: loss of the specific binding site for angiotensin IV and age-related deficit in spatial memory.

  2010cited by this paper
• Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors

  2009cited by this paper
• The neural correlates of naming and fluency deficits in Alzheimer's disease: an FDG‐PET study

  2009cited by this paper
• Cognitive Deficit in Amyloid-&bgr;–Injected Mice Was Improved by Pretreatment With a Low Dose of Telmisartan Partly Because of Peroxisome Proliferator-Activated Receptor-&ggr; Activation

  2009cited by this paper
• Angiotensin Receptor Blocker Prevented &bgr;-Amyloid–Induced Cognitive Impairment Associated With Recovery of Neurovascular Coupling

  2009cited by this paper
• Angiotensins in Alzheimer's disease - friend or foe?

  2009cited by this paper
• Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity.

  2008cited by this paper
• Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein

  2008cited by this paper
• Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

  2008cited by this paper
• Telmisartan prevented cognitive decline partly due to PPAR-gamma activation.

  2008cited by this paper
• Complete Rescue of Cerebrovascular Function in Aged Alzheimer's Disease Transgenic Mice by Antioxidants and Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist

  2008cited by this paper
• The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease

  2008cited by this paper
• Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice.

  2008cited by this paper
• Controlling Chagas' disease in urban Peru.

  2008cited by this paper
• Cognitive-enhancing effects of angiotensin IV

  2008cited by this paper
• The insulin‐regulated aminopeptidase IRAP is colocalised with GLUT4 in the mouse hippocampus – potential role in modulation of glucose uptake in neurones?

  2008cited by this paper
• Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease.

  2007cited by this paper
• Beneficial effects of losartan on vascular injury induced by advanced glycosylation end products and their receptors in spontaneous hypertension rats

  2007cited by this paper
• Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models.

  2007cited by this paper
• Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease.

  2007cited by this paper
• Accelerating Amyloid-β Fibrillization Reduces Oligomer Levels and Functional Deficits in Alzheimer Disease Mouse Models*

  2007cited by this paper
• A specific amyloid-β protein assembly in the brain impairs memory

  2006cited by this paper
• Inflammation in Alzheimer disease: driving force, bystander or beneficial response?

  2006cited by this paper
• Astrocyte control of synaptic transmission and neurovascular coupling.

  2006cited by this paper
• A specific amyloid-beta protein assembly in the brain impairs memory.

  2006cited by this paper
• Cognitive Effects Attributed to Angiotensin II may Result from its Conversion to Angiotensin IV

  2006cited by this paper
• NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide.

  2005cited by this paper
• Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease.

  2005cited by this paper
• Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease.

  2005cited by this paper
• Angiotensin II Impairs Neurovascular Coupling in Neocortex Through NADPH Oxidase–Derived Radicals

  2004cited by this paper
• Comparison of memory fMRI response among normal, MCI, and Alzheimer’s patients

  2003cited by this paper
• What Is an Angiotensin Converting Enzyme Inhibitor

  2003cited by this paper
• Effects of angiotensin II and its receptor antagonists on motor activity and anxiety in rats.

  2003cited by this paper
• The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases.

  2003cited by this paper
• Cardiology patient page. What is an angiotensin converting enzyme inhibitor?

  2003cited by this paper
• Influence of losartan and atenolol on memory function in very elderly hypertensive patients

  2003cited by this paper
• Evidence That the Angiotensin IV (AT4) Receptor Is the Enzyme Insulin-regulated Aminopeptidase*

  2001cited by this paper
• Immunocytochemical localization of angiotensin II receptor subtypes and angiotensin II with monoclonal antibodies in the rat adrenal gland.

  2001cited by this paper
• Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide.

  2001cited by this paper
• Angiotensin IV enhances LTP in rat dentate gyrus in vivo.

  2001cited by this paper
• High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation

  2000cited by this paper
• SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein

  1999cited by this paper
• Increasing required neural response to expose abnormal brain function in mild versus moderate or severe Alzheimer's disease: PET study using parametric visual stimulation.

  1998cited by this paper
• Improved electrophoretic separation and immunoblotting of beta‐amyloid (Aβ) peptides 1–40, 1–42, and 1–43

  1997cited by this paper
• Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat.

  1993cited by this paper
• Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism

  1988cited by this paper

• Neuro-renin–angiotensin–aldosterone system axis in alzheimer’s disease: from molecular dysregulation to therapeutic redirection

  2026cites this paper
• A physics-informed graph neural network to approximate docking-based binding affinity for DYRK2 in Alzheimer's drug repurposing.

  2026cites this paper
• Pharmacological and Therapeutic Innovation to Mitigate Radiation-Induced Cognitive Decline (RICD) in Brain Tumor Patients.

  2025cites this paper
• Exploring the Endoplasmic Reticulum's Role in Alzheimer's Disease and Its Potential as a Therapeutic Target

  2025cites this paper
• GPCR signaling from endosome: mechanistic insights and therapeutic potentials.

  2025cites this paper
• The application of telmisartan in central nervous system disorders

  2025cites this paper
• New insights into repurposing of renin-angiotensin system inhibitors against Alzheimer’s disease

  2024cites this paper
• Synergizing drug repurposing and target identification for neurodegenerative diseases.

  2024cites this paper
• Effects of Telmisartan on Intraocular Pressure, Blood Pressure, and Ocular Perfusion Pressure in Normal and Glaucomatous Cats

  2024cites this paper
• Age-Related Effects of AT1 Receptor Antagonist Losartan on Cognitive Decline in Spontaneously Hypertensive Rats

  2024cites this paper
• The Contribution of the Renin-Angiotensin System to Alzheimer's Disease.

  2024cites this paper
• Intranasal irbesartan reverts cognitive decline and activates the PI3K/AKT pathway in an LPS-induced neuroinflammation mice model.

  2024cites this paper
• Endoplasmic reticulum stress in Alzheimer's disease: Molecular mechanisms and therapeutic prospects.

  2023cites this paper
• Pathogenesis of Chronic Kidney Disease Is Closely Bound up with Alzheimer’s Disease, Especially via the Renin-Angiotensin System

  2023cites this paper
• A Novel Pathway Implicated in Regulating Cognitive disfunction in a Drosophila Alzheimer’s Disease Model through Acer Inhibition and CG2233 Modulation

  2023cites this paper
• Preclinical Evidence for the Role of the Yin/Yang Angiotensin System Components in Autism Spectrum Disorder: A Therapeutic Target of Astaxanthin

  2023cites this paper
• Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia

  2023cites this paper
• Higher Neuronal Facilitation and Potentiation with APOE4 Suppressed by Angiotensin II

  2023cites this paper
• Deciphering mechanisms of action of ACE inhibitors in neurodegeneration using Drosophila models of Alzheimer’s disease

  2023cites this paper
• Neuroinflammation and COVID-19 Ischemic Stroke Recovery—Evolving Evidence for the Mediating Roles of the ACE2/Angiotensin-(1–7)/Mas Receptor Axis and NLRP3 Inflammasome

  2022cites this paper
• Artificial Intelligence based Modern Approaches to Diagnose Alzheimer s

  2022cites this paper
• Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.

  2022cites this paper
• Hypertension and hyperhomocysteinemia as modifiable risk factors for Alzheimer's disease and dementia: New evidence, potential therapeutic strategies, and biomarkers

  2022cites this paper
• Renin-angiotensin-system increases phosphorylated tau and Reactive Oxygen Species in human cortical neuron cell line

  2022cites this paper
• Angiotensin receptor blocker use is associated with upregulation of the memory-protective angiotensin type 4 receptor (AT_4R) in the postmortem brains of individuals without cognitive impairment

  2022cites this paper
• Impact of New Drugs for Therapeutic Intervention in Alzheimer's Disease.

  2022cites this paper
• Targeting Brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: past, present and future.

  2022cites this paper
• Short-Term Pharmacological Induction of Arterial Stiffness and Hypertension with Angiotensin II Does Not Affect Learning and Memory and Cerebral Amyloid Load in Two Murine Models of Alzheimer’s Disease

  2022cites this paper
• mTOR Attenuation with Rapamycin Reverses Neurovascular Uncoupling and Memory Deficits in Mice Modeling Alzheimer's Disease

  2021influential citation
• Chronic Renin-Angiotensin System Activation Induced Neuroinflammation: Common Mechanisms Underlying Hypertension and Dementia?

  2021cites this paper
• The Effects and Mechanisms of Phytochemicals on Alzheimer’s Disease Neuropathology

  2021cites this paper
• Recent Advances in the Endogenous Brain Renin-Angiotensin System and Drugs Acting on It

  2021cites this paper
• Common Inflammatory Mechanisms in COVID-19 and Parkinson’s Diseases: The Role of Microbiome, Pharmabiotics and Postbiotics in Their Prevention

  2021cites this paper
• Renin-Angiotensin System Alterations in the Human Alzheimer’s Disease Brain

  2021cites this paper
• Brain Renin–Angiotensin System as Novel and Potential Therapeutic Target for Alzheimer’s Disease

  2021cites this paper
• Effects of Combined Anti-Hypertensive and Statin Treatment on Memory, Fear Extinction, Adult Neurogenesis, and Angiogenesis in Adult and Middle-Aged Mice

  2021cites this paper
• The Role of Renin Angiotensin Aldosterone System in the Progression of Cognitive Dysfunction in Chronic Kidney Disease Patients with Alzheimer’s Disease

  2021cites this paper
• Role of Neuron and Glia in Alzheimer’s Disease and Associated Vascular Dysfunction

  2021cites this paper
• Effects of valsartan on morphine tolerance and dependence in rats

  2021influential citation
• Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore.

  2021cites this paper
• Angiotensin (1–7) Expressing Probiotic as a Potential Treatment for Dementia

  2021cites this paper
• The Neurovascular Unit Dysfunction in Alzheimer’s Disease

  2021cites this paper
• Targeting impaired nutrient sensing with repurposed therapeutics to prevent or treat age-related cognitive decline and dementia: a systematic review.

  2021cites this paper
• Systemic Candesartan Treatment Modulates Behavior, Synaptic Protein Levels, and Neuroinflammation in Female Mice That Express Human APOE4

  2021cites this paper
• The beneficial effect of combination therapy with sulfasalazine and valsartan in the treatment of ulcerative colitis

  2021cites this paper
• Demonstration of age-related blood-brain barrier disruption and cerebromicrovascular rarefaction in mice by two-photon microscopy & optical coherence tomography.

  2021cites this paper
• Memory and cerebrovascular deficits recovered following angiotensin IV intervention in a mouse model of Alzheimer's disease.

  2020cites this paper
• Role of angiotensin-converting enzyme 2 in neurodegenerative diseases during the COVID-19 pandemic

  2020cites this paper
• Research Progress of Alzheimer’s Disease Therapeutic Drugs: Based on Renin-Angiotensin System Axis

  2020cites this paper
• Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Rescue Memory Defects in Drosophila-Expressing Alzheimer’s Disease-Related Transgenes Independently of the Canonical Renin Angiotensin System

  2020cites this paper
• Aβ-accelerated neurodegeneration caused by Alzheimer’s-associated ACE variant R1279Q is rescued by angiotensin system inhibition in mice

  2020cites this paper
• Brain Renin–Angiotensin System at the Intersect of Physical and Cognitive Frailty

  2020cites this paper
• The Brain AT2R—a Potential Target for Therapy in Alzheimer’s Disease and Vascular Cognitive Impairment: a Comprehensive Review of Clinical and Experimental Therapeutics

  2020cites this paper
• Vasculo-Neuronal Coupling and Neurovascular Coupling at the Neurovascular Unit: Impact of Hypertension

  2020cites this paper
• Drug repositioning and repurposing for Alzheimer disease

  2020cites this paper
• Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer’s disease

  2020cites this paper
• AT2R’s (Angiotensin II Type 2 Receptor’s) Role in Cognitive and Cerebrovascular Deficits in a Mouse Model of Alzheimer Disease

  2020cites this paper
• Adiponectin: The Potential Regulator and Therapeutic Target of Obesity and Alzheimer’s Disease

  2020cites this paper
• Brain angiotensin II and angiotensin IV receptors as potential Alzheimer’s disease therapeutic targets

  2020cites this paper
• Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing

  2020cites this paper
• Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?

  2020cites this paper
• Drug Repositioning for Alzheimer’s Disease: Finding Hidden Clues in Old Drugs

  2020cites this paper
• ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer’s disease

  2020cites this paper
• Candesartan could ameliorate the COVID-19 cytokine storm

  2020cites this paper
• Tackling Alzheimer's Disease with Existing Drugs: Playing Dirty for Bypassing Obstacles.

  2020cites this paper
• POTENTIAL PROTECTIVE EFFECTS OF ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKADE IN ALZHEIMER RAT MODEL

  2019cites this paper
• Observational Study of Brain Atrophy and Cognitive Decline Comparing a Sample of Community-Dwelling People Taking Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Over Time

  2019cites this paper
• Neurovascular coupling preserved in a chronic mouse model of Alzheimer’s disease: Methodology is critical

  2019cites this paper
• Cell Biology International

  2019cites this paper
• The Possible Role of the Angiotensin System in the Pathophysiology of Schizophrenia: Implications for Pharmacotherapy

  2019cites this paper
• Angiotensin II Receptor 1 Blockage Limits Brain Damage and Improves Functional Outcome After Brain Injury in Aged Animals Despite Age-Dependent Reduction in AT1 Expression

  2019cites this paper
• Angiotensin II triggers autophagy and apoptosis in PC12 cell line: An in vitro Alzheimer's disease model.

  2019cites this paper
• Losartan modulates brain inflammation and improves mood disorders and memory impairment induced by innate immune activation: The role of PPAR-γ activation.

  2019cites this paper
• Telmisartan ameliorates Aβ oligomer-induced inflammation via PPARγ/PTEN pathway in BV2 microglial cells.

  2019cites this paper
• Losartan Reverses Hippocampal Increase of Kynurenic Acid in Type 1 Diabetic Rats: A Novel Procognitive Aspect of Sartan Action

  2019cites this paper
• Title: Cerebrospinal fluid changes in the renin-angiotensin system in Alzheimer’s disease

  2019cites this paper
• Antihypertensive agents in Alzheimer’s disease: beyond vascular protection

  2019cites this paper
• Renin-angiotensin system and Alzheimer's disease pathophysiology: From the potential interactions to therapeutic perspectives.

  2019cites this paper
• Enhanced Cerebral Blood Volume under Normobaric Hyperoxia in the J20-hAPP Mouse Model of Alzheimer’s Disease

  2019cites this paper
• Alzheimer’s dementia: pathogenesis and impact of cardiovascular risk factors on cognitive decline

  2019cites this paper
• Transforming growth factor-β1 induces cerebrovascular dysfunction and astrogliosis through angiotensin II type 1 receptor-mediated signaling pathways.

  2018cites this paper
• Neurovascular coupling preserved in a chronic mouse model of Alzheimer’s disease: Methodology is critical

  2018influential citation
• Effects and mechanisms of actions of phytochemicals on Alzheimer's disease neuropathology.

  2018cites this paper
• Draft 1 Transforming growth factor-β 1 ( TGF-β 1 ) induces cerebrovascular dysfunction and astrogliosis through angiotensin II type 1 receptor-mediated signaling pathways

  2018influential citation
• Correction to: Pharmacologically induced impairment of neurovascular coupling responses alters gait coordination in mice

  2018cites this paper
• Targeting Renin–Angiotensin System Against Alzheimer’s Disease

  2018cites this paper
• Molecular Basis of the Brain Renin Angiotensin System in Cardiovascular and Neurologic Disorders: Uncovering a Key Role for the Astroglial Angiotensin Type 1 Receptor AT1R

  2018cites this paper
• Excessive Glutamate Stimulation Impairs ACE2 Activity Through ADAM17-Mediated Shedding in Cultured Cortical Neurons

  2018cites this paper
• Stimulation of ACE2/ANG(1–7)/Mas Axis by Diminazene Ameliorates Alzheimer’s Disease in the D-Galactose-Ovariectomized Rat Model: Role of PI3K/Akt Pathway

  2018cites this paper
• Within the Brain: The Renin Angiotensin System

  2018cites this paper
• The Time Course of Recognition Memory Impairment and Glial Pathology in the hAPP-J20 Mouse Model of Alzheimer’s Disease

  2018cites this paper
• Pleiotropic Benefits of the Angiotensin Receptor Blocker Candesartan in a Mouse Model of Alzheimer Disease

  2018cites this paper
• Connecting the brain cholesterol and renin–angiotensin systems: potential role of statins and RAS‐modifying medications in dementia

  2018cites this paper
• Angiotensin II type 1 receptor blocker losartan attenuates locomotor, anxiety-like behavior, and passive avoidance learning deficits in a sub-chronic stress model

  2018cites this paper
• Cerebrospinal Fluid Levels of Angiotensin-Converting Enzyme Are Associated with Amyloid-β42 Burden in Alzheimer’s Disease

  2018cites this paper
• Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: A systematic review and meta-analysis.

  2018cites this paper
• Implications of PI3K/AKT/PTEN Signaling on Superoxide Dismutases Expression and in the Pathogenesis of Alzheimer’s Disease

  2018cites this paper
• Candesartan ameliorates brain inflammation associated with Alzheimer's disease

  2018cites this paper
• Demonstration of impaired neurovascular coupling responses in TG2576 mouse model of Alzheimer’s disease using functional laser speckle contrast imaging

  2017cites this paper
• Review: Neuropathology and behavioural features of transgenic murine models of Alzheimer's disease

  2017cites this paper